Air Canada
AC
GoldMining Inc
GOLD
Enbridge Inc
ENB
4
BCE Inc
BCE
5
CGI Inc
GIB.A
CA Stock MarketDetailed Quotes
GENX Genix Pharmaceuticals Corp
- 0.040
- 0.0000.00%
15min DelayMarket Closed Feb 28 16:00 ET
2.37MMarket Cap-0.63P/E (TTM)
0.040High0.040Low3.00KVolume0.040Open0.040Pre Close120.00Turnover0.09052wk High0.01%Turnover Ratio59.22MShares0.02552wk Low-0.064EPS TTM1.91MFloat Cap1.050Historical HighLossP/E (Static)47.83MShs Float0.010Historical Low-0.07EPS LYR0.00%Amplitude--Dividend TTM-1.74P/B1Lot Size--Div YieldTTM
Genix Pharmaceuticals Corp Key Stats
Quarterly+Annual
YOY
| (Q3)Jul 31, 2024 | (Q2)Apr 30, 2024 | (Q1)Jan 31, 2024 | (FY)Oct 31, 2023 | (Q4)Oct 31, 2023 | (Q3)Jul 31, 2023 | (Q2)Apr 30, 2023 | (Q1)Jan 31, 2023 | (FY)Oct 31, 2022 | (Q4)Oct 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -62.75%999 | -63.96%2.91K | -95.51%71 | 12.35K | 0 | 2.68K | 8.08K | 1.58K | 0 | 0 |
| Operating revenue | -62.75%999 | -63.96%2.91K | -95.51%71 | --12.35K | --0 | --2.68K | --8.08K | --1.58K | --0 | --0 |
| Cost of revenue | -17.32%358 | -83.39%1.31K | -98.28%13 | 9.08K | 0 | 433 | 7.89K | 757 | 0 | 0 |
| Gross profit | -71.50%641 | 747.62%1.6K | -92.97%58 | 3.26K | 0 | 2.25K | 189 | 825 | 0 | 0 |
| Operating expense | -70.96%48.33K | -77.39%49.72K | -79.20%47.32K | -14.26%884.16K | 16.76%270.3K | -32.98%166.44K | -1.40%219.88K | -30.71%227.54K | -37.69%1.03M | -37.15%231.5K |
| Selling and administrative expenses | 74.72%40.16K | -40.53%46.68K | -49.17%43.12K | -34.44%278.83K | 32.20%106K | -72.63%22.99K | 0.13%78.5K | -54.36%84.84K | -59.63%425.32K | -54.25%80.18K |
| -Selling and marketing expense | --0 | 61.16%1.14K | --300 | 148.04%4.8K | 95.92%3.79K | --300 | --708 | --0 | --1.93K | --1.93K |
| -General and administrative expense | 77.03%40.16K | -41.46%45.54K | -49.53%42.82K | -35.28%274.03K | 30.63%102.21K | -72.99%22.69K | -0.78%77.79K | -54.36%84.84K | -59.82%423.39K | -55.35%78.24K |
| Depreciation amortization depletion | -99.79%283 | -99.79%283 | -99.80%283 | -2.97%547.42K | -2.44%135.92K | -4.04%135.92K | -2.99%137.42K | -2.40%138.16K | 5.14%564.17K | -14.07%139.32K |
| -Depreciation and amortization | -99.79%283 | -99.79%283 | -99.80%283 | -2.97%547.42K | -2.44%135.92K | -4.04%135.92K | -2.99%137.42K | -2.40%138.16K | 5.14%564.17K | -14.07%139.32K |
| Other operating expenses | 4.66%7.88K | -30.56%2.75K | -13.75%3.91K | 38.81%57.91K | 136.44%28.38K | -66.83%7.53K | 34.37%3.96K | 399.23%4.54K | -35.49%41.72K | -61.21%12K |
| Operating profit | 70.96%-47.68K | 78.10%-48.12K | 79.15%-47.26K | 14.58%-880.89K | -16.76%-270.3K | 33.89%-164.19K | 1.48%-219.69K | 30.96%-226.72K | 37.69%-1.03M | 37.15%-231.5K |
| Net non-operating interest income (expenses) | -225.09%-32.67K | -227.63%-28.96K | -219.81%-23.86K | -333.29%-51.93K | -484.71%-25.58K | -149.75%-10.05K | -254.94%-8.84K | -580.75%-7.46K | -482.64%-11.99K | -100.50%-4.38K |
| Non-operating interest income | 45.95%54 | -49.22%65 | -74.81%33 | 139.19%354 | 61.11%58 | 0.00%37 | 392.31%128 | 167.35%131 | -89.81%148 | -60.00%36 |
| Non-operating interest expense | 224.44%32.73K | 223.68%29.02K | 214.73%23.89K | 374.35%50.98K | 704.40%24.33K | 148.39%10.09K | 256.36%8.97K | 563.06%7.59K | 206.27%10.75K | 33.14%3.03K |
| Total other finance cost | ---- | ---- | ---- | -5.77%1.31K | ---- | ---- | ---- | ---- | --1.39K | ---- |
| Other net income (expenses) | -117.91%-1.82K | -61.54%-8.87K | 68.94%12.07K | -11,143.79%-3.46M | -17,496.17%-3.47M | 10.14K | -170.14%-5.49K | 179.19%7.14K | -788.66%-30.8K | -1,116.79%-19.75K |
| Gain on sale of security | -117.91%-1.82K | -61.54%-8.87K | 68.94%12.07K | 80.92%-5.88K | 10.54%-17.67K | --10.14K | -170.14%-5.49K | 179.19%7.14K | -788.66%-30.8K | -1,116.79%-19.75K |
| Special income (charges) | ---- | ---- | ---- | ---3.46M | ---- | ---- | ---- | ---- | --0 | ---- |
| -Less:Impairment of capital assets | ---- | ---- | ---- | --3.46M | ---- | ---- | ---- | ---- | --0 | ---- |
| Income before tax | 49.93%-82.17K | 63.28%-85.94K | 73.99%-59.06K | -309.27%-4.4M | -1,374.99%-3.77M | 34.97%-164.1K | -2.86%-234.02K | 32.93%-227.04K | 35.01%-1.07M | 30.64%-255.62K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 49.93%-82.17K | 63.28%-85.94K | 73.99%-59.06K | -309.27%-4.4M | -1,374.99%-3.77M | 34.97%-164.1K | -2.86%-234.02K | 32.93%-227.04K | 35.01%-1.07M | 30.64%-255.62K |
| Net income continuous operations | 49.93%-82.17K | 63.28%-85.94K | 73.99%-59.06K | -309.27%-4.4M | -1,374.99%-3.77M | 34.97%-164.1K | -2.86%-234.02K | 32.93%-227.04K | 35.01%-1.07M | 30.64%-255.62K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 49.93%-82.17K | 63.28%-85.94K | 73.99%-59.06K | -309.27%-4.4M | -1,374.99%-3.77M | 34.97%-164.1K | -2.86%-234.02K | 32.93%-227.04K | 35.01%-1.07M | 30.64%-255.62K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 49.93%-82.17K | 63.28%-85.94K | 73.99%-59.06K | -309.27%-4.4M | -1,374.99%-3.77M | 34.97%-164.1K | -2.86%-234.02K | 32.93%-227.04K | 35.01%-1.07M | 30.64%-255.62K |
| Diluted earnings per share | 49.95%-0.0014 | 63.28%-0.0015 | 74.00%-0.001 | -250.00%-0.07 | -500.00%-0.06 | 34.97%-0.0028 | -2.84%-0.004 | 61.66%-0.0038 | 33.33%-0.02 | 0.00%-0.01 |
| Basic earnings per share | 49.95%-0.0014 | 63.28%-0.0015 | 74.00%-0.001 | -250.00%-0.07 | -500.00%-0.06 | 34.97%-0.0028 | -2.84%-0.004 | 61.66%-0.0038 | 33.33%-0.02 | 0.00%-0.01 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.